drugset / Trial / NCT07361679

LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

NCT07361679

Phase 4 Recruiting 100 enrolled Alexandra Hospital, Athens, Greece
RandomizedParallel-groupOpen-labelPrevention

Summary

Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women. Low molecular weight heparin (LMWH) has shown potential benefits in addition to aspirin for preventing preeclampsia through its anticoagulant, anti-inflammatory, and endothelial protective effects. However, current evidence is limited and conflicting regarding the added value of LMWH to aspirin. This randomized controlled trial aims to evaluate the efficacy of combined aspirin and LMWH, compared to aspirin alone, for reducing the incidence of preeclampsia in high-risk gravidas.

Timeline

Start
2023-01-18
Primary completion
2026-08-01
Completion
2027-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tinzaparin Other / unclassified 4500 iu Subcutaneous
Subject Tinzaparin Other / unclassified 6000 iu Subcutaneous
Subject Tinzaparin Other / unclassified 8000 iu Subcutaneous
Background Aspirin Small molecule 160 mg Oral

Indications